Cargando…
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?
Biologics are increasingly being co‐developed in combination or as novel constructs like bispecific antibodies (BsAbs) with the goal of targeting multiple, non‐redundant mechanisms of action. Rational design of combinations and dual‐targeting approaches that consider disease complexities have the po...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468564/ https://www.ncbi.nlm.nih.gov/pubmed/35611545 http://dx.doi.org/10.1111/cts.13345 |